Nicole Hawthorne, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 125 Middletown Rd, Waterford, NY 12188 Phone: 518-587-8008 Fax: 518-587-8241 |
News Archive
A carbohydrate isolated from the liver lowers blood sugar levels after it is injected into diabetic rats, according to research carried out by a team of experts at the University of Virginia Health System (UVHS).
New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.
Haiti's cholera outbreak appears to have spread to its capital, "imperiling nearly 3 million people living in Port-au-Prince, nearly half of them in unsanitary tent camps for the homeless from the Jan. 12 earthquake," the Associated Press/KIRO reports.
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
› Verified 6 days ago